Opinion|Videos|September 3, 2025

Highlighting Deuruxolitinib for Alopecia Areata

Panelists discuss how deuruxolitinib, evaluated in the THRIVE-AA1 and THRIVE-AA2 phase 3 trials, differs from previous Janus kinase (JAK) inhibitors in its formulation and efficacy, and why ensuring long-term patient adherence through 24 weeks is crucial for treatment durability and success.

Video content above is prompted by the following:

  1. Mostaghimi: Deuruxolitinib has been evaluated in the THRIVE-AA1 and THRIVE-AA2 multinational phase 3 clinical trials gaining FDA approval in 2024. How did this JAK inhibitor differ from the last past two 2 JAK inhibitors approved in the previous 2 years?
    1. Durability is often an issue seen in studies where patients don’t remain on therapies long-term. Why is it so important to see the majority of patients staying on deuruxolitinib through 24 weeks?
    2. How does the durability of the different JAK inhibitors compare?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo